Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.54 |
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.41 |
| ▸ | CCR9 | P51686 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14270619 | 0.96 | PPARG (0.50) | PPARGPPARACCR2FOLH1TP53 | |
| SCHEMBL2807510 | 0.90 | PPARG (0.47) | PPARGPPARAFOLH1TP53 | |
| Gsk-376501 SCHEMBL29810243 | 0.86 | SERPINE1 (0.54) | PPARGCCR2FOLH1SERPINE1EDNRB | |
| Gsk-376501 SCHEMBL2813131 | 0.86 | SERPINE1 (0.54) | PPARGCCR2FOLH1SERPINE1EDNRB | |
| SCHEMBL2809836 | 0.84 | SERPINE1 (0.50) | PPARGCCR2FOLH1TP53SERPINE1 | |
| SCHEMBL2812683 | 0.82 | SERPINE1 (0.51) | PPARGFOLH1SERPINE1EDNRBEDNRA | |
| SCHEMBL2807083 | 0.81 | SERPINE1 (0.51) | PPARGCCR2FOLH1SERPINE1EDNRB | |
| SCHEMBL2809577 | 0.80 | PPARG (0.51) | PPARGPPARAFOLH1SERPINE1EDNRB | |
| SCHEMBL2811186 | 0.80 | SERPINE1 (0.48) | PPARGCCR2FOLH1SERPINE1EDNRB | |
| SCHEMBL2811759 | 0.80 | SERPINE1 (0.48) | PPARGFOLH1SERPINE1EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | claimed |
| EP-2081894-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SmithKline Beecham Corporation (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | claimed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2081894-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SmithKline Beecham Corporation (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885CCR2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.